Abstract
Background
5-Hydroxymethylcytosine-enriched gene profiles and regions show tissue-specific and tumor specific. There is a potential value to explore cell-free DNA 5-hydroxymethylcytosine feature biomarkers for early gastric cancer detection.
Methods
A matched case‒control study design with 50 gastric cancer patients and 50 controls was performed to sequence the different 5-hydroxymethylcytosine modification features of cell free DNA. Significantly differential 5-hydroxymethylcytosine modification genes were identified to construct a gastric cancer diagnostic model. Data set from GEO was used as an external testing set to test the robustness of the diagnostic model.
Results
Accounting for more than 90% of 5-hydroxymethylcytosine peaks were distributed in the gene body in both the gastric cancer and control groups. The diagnostic model was developed based on five different 5-hydroxymethylcytosine modification genes, FBXL7, PDE3A, TPO, SNTG2 and STXBP5. The model could effectively distinguish gastric cancer patients from controls in the training (AUC = 0.95, sensitivity = 88.6%, specificity = 94.3%), validation (AUC = 0.87, sensitivity = 73.3%, specificity = 93.3%) and testing (AUC = 0.90, sensitivity = 81.9%, specificity = 90.2%) sets. The risk scores of the controls from the model were significantly lower than those of gastric cancer patients in both our own data (P < 0.001) and GEO external testing data (P < 0.001), and no significant difference between different TNM stage patients (P = 0.09 and 0.66). Furthermore, there was no significant difference between the healthy control and benign gastric disease patients in the testing set from GEO (P = 0.10).
Conclusions
The characteristics of 5-hydroxymethylcytosine in cell free DNA are specific to gastric cancer patients, and the diagnostic model constructed by five genes’ 5-hydroxymethylcytosine features could effectively identify gastric cancer patients.
Similar content being viewed by others
Data availability
The raw and processed 5hmc-Seal data of the model development in the current study are available in GEO database as GSE246110.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 cancers in countries. CA Cancer journal for clinicians. 2021;71(209):249.
Sumiyama K. Past and current trends in endoscopic diagnosis for early stage gastric cancer in Japan. Gastric cancer : Off J Intern Gastric Cancer Assoc Japanese Gastric Cancer Assoc. 2017;20(Suppl 1):20–7.
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England). 2018;391(10125):1023–75.
Isobe Y, Nashimoto A, Akazawa K, Oda I, Hayashi K, Miyashiro I, et al. Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric Cancer. 2011;14(4):301–16.
Mabe K, Inoue K, Kamada T, Kato K, Kato M, Haruma K. Endoscopic screening for gastric cancer in Japan: current status and future perspectives. Dig Endosc. 2022;34(3):412–9.
Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M. Gastric cancer: prevention, screening and early diagnosis. World J Gastroenterol. 2014;20(38):13842–62.
Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the task force of the Japanese gastric cancer association. Gastric Cancer. 2014;17(1):26–33.
Feng F, Tian Y, Xu G, Liu Z, Liu S, Zheng G, et al. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer. BMC Cancer. 2017;17(1):737.
Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008;9(3):279–87.
Ikeda F, Shikata K, Hata J, Fukuhara M, Hirakawa Y, Ohara T, et al. Combination of helicobacter pylori antibody and serum pepsinogen as a good predictive tool of gastric cancer incidence: 20-year prospective data from the hisayama study. J Epidemiol. 2016;26(12):629–36.
Huang YK, Yu JC, Kang WM, Ma ZQ, Ye X, Tian SB, et al. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: a systematic review and meta-analysis. PLoS ONE. 2015;10(11): e0142080.
Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA. 2005;102(45):16368–73.
Campos-Carrillo A, Weitzel JN, Sahoo P, Rockne R, Mokhnatkin JV, Murtaza M, et al. Circulating tumor DNA as an early cancer detection tool. Pharmacol Ther. 2020;207: 107458.
Xu RH, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 2017;16(11):1155–61.
Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Annals oncol off JEur Soc Med Oncol. 2021;32(2):229–39.
Morris JPT, Yashinskie JJ, Koche R, Chandwani R, Tian S, Chen CC, et al. α-Ketoglutarate links p53 to cell fate during tumour suppression. Nature. 2019;573(7775):595–9. https://doi.org/10.1038/s41586-019-1577-5.
Al-Mahdawi S, Virmouni SA, Pook MA. The emerging role of 5-hydroxymethylcytosine in neurodegenerative diseases. Front Neurosci. 2014;8:397.
Jiang D, Sun M, You L, Lu K, Gao L, Hu C, et al. DNA methylation and hydroxymethylation are associated with the degree of coronary atherosclerosis in elderly patients with coronary heart disease. Life Sci. 2019;224:241–8.
Prikrylova T, Robertson J, Ferrucci F, Konorska D, Aanes H, Manaf A, et al. 5-hydroxymethylcytosine marks mammalian origins acting as a barrier to replication. Sci Rep. 2019;9(1):11065.
Skvortsova K, Stirzaker C, Taberlay P. The DNA methylation landscape in cancer. Essays Biochem. 2019;63(6):797–811.
Li W, Zhang X, Lu X, You L, Song Y, Luo Z, et al. 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers. Cell Res. 2017;27(10):1243–57.
Song CX, Szulwach KE, Fu Y, Dai Q, Yi C, Li X, et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol. 2011;29(1):68–72.
Xiao Z, Wu W, Wu C, Li M, Sun F, Zheng L, et al. 5-Hydroxymethylcytosine signature in circulating cell-free DNA as a potential diagnostic factor for early-stage colorectal cancer and precancerous adenoma. Mol Oncol. 2021;15(1):138–50.
Guler GD, Ning Y, Ku CJ, Phillips T, McCarthy E, Ellison CK, et al. Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA. Nat Commun. 2020;11(1):5270.
Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J Royal Statist Soc, Series B. 1995;57:289–300.
Pfeifer GP, Szabó PE. Gene body profiles of 5-hydroxymethylcytosine: potential origin, function and use as a cancer biomarker. Epigenomics. 2018;10(8):1029–32.
Qi J, Shi Y, Tan Y, Zhang Q, Zhang J, Wang J, et al. Regional gain and global loss of 5-hydroxymethylcytosine coexist in genitourinary cancers and regulate different oncogenic pathways. Clin Epigenetics. 2022;14(1):117.
Zhang J, Han X, Gao C, Xing Y, Qi Z, Liu R, et al. 5-Hydroxymethylome in circulating cell-free dna as a potential biomarker for non-small-cell lung cancer. Genom Proteom Bioinform. 2018;16(3):187–99.
Gao P, Lin S, Cai M, Zhu Y, Song Y, Sui Y, et al. 5-Hydroxymethylcytosine profiling from genomic and cell-free DNA for colorectal cancers patients. J Cell Mol Med. 2019;23(5):3530–7.
Cao F, Wei A, Hu X, He Y, Zhang J, Xia L, et al. Integrated epigenetic biomarkers in circulating cell-free DNA as a robust classifier for pancreatic cancer. Clin Epigenetics. 2020;12(1):112.
Cai Z, Zhang J, He Y, Xia L, Dong X, Chen G, et al. Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma. ESMO open. 2021;6(1): 100021.
Wen L, Tang F. Genomic distribution and possible functions of DNA hydroxymethylation in the brain. Genomics. 2014;104(5):341–6.
Gross JA, Pacis A, Chen GG, Drupals M, Lutz PE, Barreiro LB, et al. Gene-body 5-hydroxymethylation is associated with gene expression changes in the prefrontal cortex of depressed individuals. Transl Psychiatry. 2017;7(5): e1119.
Colquitt BM, Allen WE, Barnea G, Lomvardas S. Alteration of genic 5-hydroxymethylcytosine patterning in olfactory neurons correlates with changes in gene expression and cell identity. Proc Natl Acad Sci USA. 2013;110(36):14682–7.
Cai J, Chen L, Zhang Z, Zhang X, Lu X, Liu W, et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut. 2019;68(12):2195–205.
Cai J, Zeng C, Hua W, Qi Z, Song Y, Lu X, et al. An integrative analysis of genome-wide 5-hydroxymethylcytosines in circulating cell-free DNA detects noninvasive diagnostic markers for gliomas. Neuro-oncology advances. 2021. https://doi.org/10.1093/noajnl/vdab049.
Shen L, Song CX, He C, Zhang Y. Mechanism and function of oxidative reversal of DNA and RNA methylation. Annu Rev Biochem. 2014;83:585–614.
Stolz P, Mantero AS, Tvardovskiy A, Ugur E, Wange LE, Mulholland CB, et al. TET1 regulates gene expression and repression of endogenous retroviruses independent of DNA demethylation. Nucleic Acids Res. 2022;50(15):8491–511.
Han D, Lu X, Shih AH, Nie J, You Q, Xu MM, et al. A highly sensitive and robust method for genome-wide 5hmc profiling of rare cell populations. Mol Cell. 2016;63(4):711–9.
Ponnaluri VK, Ehrlich KC, Zhang G, Lacey M, Johnston D, Pradhan S, et al. Association of 5-hydroxymethylation and 5-methylation of DNA cytosine with tissue-specific gene expression. Epigenetics. 2017;12(2):123–38.
Wagner N, Wagner KD. The role of PPARs in disease. Cells. 2020. https://doi.org/10.3390/cells9112367.
Kamran M, Long ZJ, Xu D, Lv SS, Liu B, Wang CL, et al. Aurora kinase a regulates survivin stability through targeting FBXL7 in gastric cancer drug resistance and prognosis. Oncogenesis. 2017;6(2): e298.
Wang Y, Shen X, Gong L, Zhao Y, Xiong X. Functional characterization of FBXL7 as a novel player in human cancers. Cell death discovery. 2022;8(1):342.
Wang J, Yang L, Li Y, Wang XB, Yang W, Liu F, et al. Aberrant hypermethylation induced downregulation of antisense lncRNA STXBP5-AS1 and its sense gene STXBP5 correlate with tumorigenesis of glioma. Life Sci. 2021;278: 119590.
Cen D, Huang H, Yang L, Guo K, Zhang J. Long noncoding RNA STXBP5-AS1 inhibits cell proliferation, migration, and invasion through inhibiting the PI3K/AKT signaling pathway in gastric cancer cells. Onco Targets Ther. 2019;12:1929–36.
Shao S, Wang C, Wang S, Zhang H, Zhang Y. LncRNA STXBP5-AS1 suppressed cervical cancer progression via targeting miR-96–5p/PTEN axis. Biomed Pharmacother Biomed Pharmacother. 2019. https://doi.org/10.1016/j.biopha.2019.109082.
Acknowledgements
We thank the supporting from the National Natural Science Foundation of China (81874279 and 82373664), Natural Science Foundation of Jilin Province (YDZJ202201ZYTS064), and the Department of Finance Jilin Province (JLSWSRCZX2021-073).
Funding
Naural Science Foundation of Jilin Province, YDZJ202201ZYTS064, Yingli Fu, National Natural Science Foundation of China, 81874279, Jing Jiang, 82373664, Jing Jiang, Department of Finance of Jilin Province, JLSWSRCZX2021-073, Xueyuan Cao.
Author information
Authors and Affiliations
Contributions
Yingli Fu and Jing Jiang conceptualized and wrote the main text and figures, Yingli Fu and Jing Jiang contributed equally. Xueyuan Cao, Yanhua Wu and Zhifang Jia analyzed information and made suggestions for improvement. Donghui Cao, Yangyu Zhang, Dongming Li, Yingnan Cui, and Yuzheng Zhang revised the overall text to provide accuracy. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Ethics approval and consent to participate
This study was reviewed and approved by the Ethics Committee at The First Hospital of Jilin University (NO. 19K118-001). Written informed consent was obtained from each participant, and biospecimens were collected as approved by the Institutional Review Boards (IRBs) responsible at the First Hospital of Jilin University.
Consent for publication
All authors give consent for the publication of the manuscript.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
10120_2024_1493_MOESM8_ESM.eps
Supplementary file8 Fig. 1.Classification value of model involved each individual gene and the model distinguish probability for other type of cancer.( a.ROC curves for each individual gene 5hmC level and the complex predicted score with combined data of our own data and GEO validation data. b.ROC curves for the colon, liver, pancreas and thyroid cancer separately with data from the GEO data (GSE98570).) (EPS 2127 KB)
10120_2024_1493_MOESM9_ESM.eps
Supplementary file9 Fig. 2. Correlation between 5hmC change and gene expression.(a.The log2 fold change of 5hmC in GC patients’ cfDNA vs. controls’ cfDNA were compared to the log2 fold change of 5hmC in tumor vs. adjacent tissues. 5hmC changes in the tumor is positively associated with 5hmC changes in the cfDNA for 350 genes with different 5hmC. b.The log2 fold changes of gene expression in tumor vs. adjacent tissues were compared to the log2 fold change of 5hmC in tumor vs. adjacent tissues. Gene expression changes in the tumor is positively associated with 5hmC changes in the tumor for 350 5hmC differential genes.) (EPS 2994 KB)
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Fu, Y., Jiang, J., Wu, Y. et al. Genome-wide 5-hydroxymethylcytosines in circulating cell-free DNA as noninvasive diagnostic markers for gastric cancer. Gastric Cancer (2024). https://doi.org/10.1007/s10120-024-01493-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10120-024-01493-7